Michelle A. Albert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle A. Albert has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Joan Staggers
1 shared publicationNader Rifai
Department of Laboratory Medicine, Children’s Hospital, Harvard Medical School, Boston, MA, USA
1 shared publicationPaul Chew
1 shared publicationPaul M Ridker
Center for Cardiovascular Disease Prevention and the Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disease, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
1 shared publicationPaul M. Ridker
1 shared publication
Latest Publications
- Open Access
- 1 August 2001
- Published by SAGE Publications in Vascular Medicine
- Vol. 6 (3) , 145-149
Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis
Cystatin-C, a cysteine protease inhibitor, and mannose binding lectin, an innate defense protein involved in microbial clearance, have both been hypothesized to mediate atherosclerotic plaque progression. Prospective data evaluating whether levels of these proteins are associated with incident cardiovascular disease are sparse. Employing a prospective, nested, case-control study design, baseline levels of cystatin-C and mannose binding protein were evaluated among 133 apparently healthy men who subsequently developed symptomatic peripheral arterial disease (cases) and among 133 age- and smoking-matched controls who remained free of reported vascular disease during 5 years of follow-up. Overall, median baseline levels of cystatin-C were virtually identical among case and control subjects (0.83 mg/l, p = 0.84), whereas median baseline levels of mannose binding protein among cases and controls were 2.32 mg/l and 2.20 mg/l respectively (p = 0.69). No evidence of association was found between either cystatin-C or mannose binding protein and the development of peripheral arterial disease in analyses evaluating for linear trends or for threshold effects (all p-values ≤ 0.05). In contrast with prior retrospective and cross-sectional studies, no evidence was found that baseline levels of cystatin-C or mannose binding protein are associated with an increased risk of future arterial disease.
- 1 August 2001
- Published by SAGE Publications in Vascular Medicine
- Vol. 6 (3) , 145-149
Open AccessPlasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis
Cystatin-C, a cysteine protease inhibitor, and mannose binding lectin, an innate defense protein involved in microbial clearance, have both been hypothesized to mediate atherosclerotic plaque progression. Prospective data evaluating whether levels of these proteins are associated with incident cardiovascular disease are sparse. Employing a prospective, nested, case-control study design, baseline levels of cystatin-C and mannose binding protein were evaluated among 133 apparently healthy men who subsequently developed symptomatic peripheral arterial disease (cases) and among 133 age- and smoking-matched controls who remained free of reported vascular disease during 5 years of follow-up. Overall, median baseline levels of cystatin-C were virtually identical among case and control subjects (0.83 mg/l, p = 0.84), whereas median baseline levels of mannose binding protein among cases and controls were 2.32 mg/l and 2.20 mg/l respectively (p = 0.69). No evidence of association was found between either cystatin-C or mannose binding protein and the development of peripheral arterial disease in analyses evaluating for linear trends or for threshold effects (all p-values ≤ 0.05). In contrast with prior retrospective and cross-sectional studies, no evidence was found that baseline levels of cystatin-C or mannose binding protein are associated with an increased risk of future arterial disease.
- 1 June 2001
- Published by Elsevier in American Heart Journal
- Vol. 141 (6) , 893-898
The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design
- 1 June 2001
- Published by Elsevier in American Heart Journal
- Vol. 141 (6) , 893-898
The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design
- 1 July 2000
- Published by Springer Nature in Current Cardiology Reports
- Vol. 2 (4) , 274-279
The role of C-reactive protein in cardiovascular disease risk
Over the past few years, a flurry of data in the medical literature has strongly implicated C-reactive protein (CRP) as a marker of inflammation in coronary artery disease (CAD). Recognizing the likely integral role that inflammation plays in the pathogenesis of atherosclerosis, many hospital laboratories have tests to measure CRP concentration in the clinical setting. However, the clinical use of these tests still need definition. To date, of the plasma-based markers investigated, CRP provides the strongest risk prediction for cardiovascular disease in men and women. Questions remain regarding the degree to which CRP can improve risk stratification beyond that of the traditional risk factors of CAD.
- 1 July 2000
- Published by Springer Nature in Current Cardiology Reports
- Vol. 2 (4) , 274-279
The role of C-reactive protein in cardiovascular disease risk
Over the past few years, a flurry of data in the medical literature has strongly implicated C-reactive protein (CRP) as a marker of inflammation in coronary artery disease (CAD). Recognizing the likely integral role that inflammation plays in the pathogenesis of atherosclerosis, many hospital laboratories have tests to measure CRP concentration in the clinical setting. However, the clinical use of these tests still need definition. To date, of the plasma-based markers investigated, CRP provides the strongest risk prediction for cardiovascular disease in men and women. Questions remain regarding the degree to which CRP can improve risk stratification beyond that of the traditional risk factors of CAD.